REGENXBIO Inc.
RGNX · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Malzahn Craig: Form 4
Insider disclosure · Filed · Report period 01 Sep 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- RGNX · 75901B107 - Common Stock, par value $0.0001 per share
Company details and SEC sources
CIK 0001590877 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- RGNX on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 9804 Medical Center Drive, Rockville, MD, 20850
- Fiscal year end
- 31 December
- Former names on EDGAR
- ReGenX Biosciences, LLC (to 07 Nov 2013)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields